Cargando…

What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?

Detalles Bibliográficos
Autores principales:	De Lorenzis, Enrico, Natalello, Gerlando, Gigante, Laura, Verardi, Lucrezia, Bosello, Silvia Laura, Gremese, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489246/ https://www.ncbi.nlm.nih.gov/pubmed/32942036 http://dx.doi.org/10.1016/j.autrev.2020.102666

Ejemplares similares

Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement
por: De Lorenzis, Enrico, et al.
Publicado: (2020)

Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic
por: De Lorenzis, Enrico, et al.
Publicado: (2022)

Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement()
por: Natalello, Gerlando, et al.
Publicado: (2021)

No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic
por: Alivernini, Stefano, et al.
Publicado: (2020)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

Chronic related group classification system as a new public health tool to predict risk and outcome of COVID-19 in patients with systemic rheumatic diseases: A population-based study of more than forty thousand patients
por: De Lorenzis, Enrico, et al.
Publicado: (2023)

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease
por: Levasseur, Kirsty, et al.
Publicado: (2019)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
por: Mehta, Asmita A, et al.
Publicado: (2021)

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model
por: Guo, Jinqiang, et al.
Publicado: (2023)

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)

Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease
por: Li, Liubing, et al.
Publicado: (2017)

Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship?
por: De Lorenzis, Enrico, et al.
Publicado: (2021)

Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis
por: Li, Yuhui, et al.
Publicado: (2020)

Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease—an Auckland case series
por: Dick, Michael, et al.
Publicado: (2021)

Acral Cutaneous Ulcerations and Livedo Reticularis with Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Classical Dermatomyositis
por: Wongjirattikarn, Rachot, et al.
Publicado: (2020)

Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome
por: Zuo, Yu, et al.
Publicado: (2022)

Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine
por: Kawamoto, Shinya, et al.
Publicado: (2021)

Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody
por: Wang, Huyan, et al.
Publicado: (2023)

Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
por: Ikeda, Satoshi, et al.
Publicado: (2015)

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
por: Aissaoui, Houari, et al.
Publicado: (2021)

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report
por: Endo, Yushiro, et al.
Publicado: (2018)

Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient
por: Li, Zi Ying, et al.
Publicado: (2020)

Anti-MDA5 Positive Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease and Correlation between Serum Ferritin Level and Treatment Response
por: Zohar, Daniela Noa, et al.
Publicado: (2020)

7. Anti-MDA5 associated dermatomyositis
por: Laverty, Ursula, et al.
Publicado: (2019)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level
por: Osawa, Takeshi, et al.
Publicado: (2017)

Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports
por: Takahashi, Rina, et al.
Publicado: (2021)

Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: A case report and literature review
por: Lu, Ci, et al.
Publicado: (2023)

Pneumomediastinum in MDA5-associated clinically amyopathic dermatomyositis
por: Kotsiou, Ourania S., et al.
Publicado: (2017)

Therapiealternativen bei amyopathischer MDA5-positiver Dermatomyositis
por: Schumacher, Falk, et al.
Publicado: (2023)

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis Complicated by Unilateral Right-sided Interstitial Lung Disease
por: Kori, Mayuko, et al.
Publicado: (2020)

Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease
por: Liang, Lin, et al.
Publicado: (2021)

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies
por: Hiramatsu, Toshiya, et al.
Publicado: (2022)

Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis
por: Strauss, Timmy, et al.
Publicado: (2023)

Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review
por: Yeung, Tsz-Wing, et al.
Publicado: (2021)

Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022)

A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Anti-MDA5 Antibody-Positive Interstitial Pneumonia with Autoimmune Features Presenting as Amyopathic Hypodermatitic Dermatomyositis: A Case Report
por: Mihailescu, Maria L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1k9kpmnpadh1f6e8cbm6dhtvja